Publications

Filter by year

Filter by type

Filter by year

Showing all years

Identifying Predictors and Correlates of Skin Disease Self-Stigma for Online RCT Intervention: A systematic review

CFZ. Stuhlmann, J. Traxler, V. Paucke, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Disease burden and patient-defined treatment needs and benefits in patients with psoriasis with and without anogenital involvement

N. da Silva, M. Augustin, D. Wilsmann-Theis, A. Tsianakas, P. Staubach-Renz, R. Sommer

Poster presented at the EADV Congress 2023, Berlin, Germany.

Everybody Copes: An Interprofessional Workshop on Stress, Coping, and Helping Primary Care Patients Manage Medical Stressors

CFZ. Stuhlmann, H. Spellman, DJ. Coletti

The value of psychological principles has become apparent in medical settings, especially with the rise of patient-centered care. We aimed to provide a curriculum informing medical providers about the theoretical basis and clinical utility of the social-cognitive model of stress and coping.

PMID:
36798526
DOI:
https://doi.org/10.15766/mep_2374-8265.11300

Predictors of and Interventions Against Self Stigmatisation Results of Two Systematic Reviews

J. Traxler, CFZ. Stuhlmann, V. Paucke, L. Westphal, H. Graf & R. Sommer

Poster presented at the EADV Congress 2023, Berlin, Germany.

Entwicklung neuer Messinstrumente zur Erfassung von Cumulative Life Course Impairments (CLCI) bei chronisch-entzündlichen Hautkrankheiten

C. Braren-von Stülpnagel, M. Augustin, L. Westphal, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Development of Measurement Tools to Assess Cumulative Life Course Impairment in Patients with Chronic Skin Diseases

C.C. Braren-von Stülpnagel, M. Augustin, L. Westphal, R. Sommer

Patients with chronic skin diseases suffer from physical, psychological, emotional and social impairments. The overall burden has significant impact on patients' life, contributing to irreversible damage across many domains, known as cumulative life course impairment (CLCI). The aim of this project was to develop instruments which (a) measure persisting CLCI and (b) identify patients at risk for developing future CLCI.

PMID:
36807404
DOI:
https://doi.org/10.1111/jdv.18977

Psychosocial health and quality of life in ICSI and naturally conceived adolescents: a cross-sectional comparison

N. Eisemann, M. Schnoor, E. Rakuska, C.C. Braren-von Stülpnagel, A. Katalinic, M. Ludwig, B. Sonntag, A.K. Ludwig & S.A. Elsner

Psychosocial health (PH) and quality of life (QoL) are important health outcomes. We compared PH and QoL of adolescents conceived with intrazytoplasmatic sperm injection (ICSI) and of naturally conceived controls. The impact of disclosure of ICSI-conception on QoL and PH was quantified.

PMID:
36928650
DOI:
https://doi.org/10.1007/s11136-023-03382-5

Patient-reported Well-being in Value-based Care Using Tildrakizumab in a Real-world Setting: Protocol of a Multinational, Phase IV, 1-cohort Prospective Observational Study (the POSITIVE Study)

M. Augustin, R. Sommer, E. Daudén, P. Laws, E. de Jong, G. Fabbrocini, L. Naldi, A. Navarini, J. Lambert, Z. Reguiai, S. Gerdes, E. Massana, T. Obis, I. Kasujee, U. Mrowietz

Psoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life of patients and their families. However, the most commonly used decision-making tools in psoriasis, Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), do not fully capture the impact of psoriasis on patients' lives. In contrast, the well-established 5-item WHO Well-being Index (WHO-5) assesses the subjective psychological well-being of patients. Moreover, while drug innovations became available for psoriasis, data on the impact of these therapies on patients' lives and their closest environment (family, physicians) are limited. This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-severe psoriasis. Moreover, the long-term benefit of tildrakizumab on physicians' satisfaction and partners' lives of patients with psoriasis will be evaluated.

PMID:
36792337
DOI:
https://doi.org/10.1136/bmjopen-2021-060536

Implementing Wellbeing in the Management of Psoriasis: An Expert Recommendation

R. Sommer, U. Mrowietz, K. Gaarn du Jardin, I. Kasujee, E. Martini, E. Daudén, G. Fabbrocini, A. Zink, C.E.M. Griffiths, M. Augustin

The main objective of this expert review is to give the concept of well-being a place as an entity within the holistic therapeutic approach for patients with psoriasis. Identifying and defining common goals beyond the skin with the patient and testing them throughout the course of treatment will benefit and enhance treatment success. We propose a series of recommendations for application in clinical practice, providing tangible clinical guidance for implementing well-being in the management of psoriasis.

PMID:
37822008
DOI:
10.1111/jdv.19567

Exploring the burden of xerosis cutis and the impact of dermatological skin care from patient's perspective

C. Braren-von Stülpnagel, M. Augustin, N. da Silva, R. Sommer

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

<< < 1 2 3 4 5 6 … 20 > >>